MediWound Ltd.(MDWD)Earnings, Financials & Key Ratios
MDWD•NASDAQ
Price updated Jun 19, 2026
AboutMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Show more
- Revenue$17M-16.1%
- EBITDA-$23M-30.8%
- Net Income-$24M+21.0%
- EPS (Diluted)-2.10+30.7%
- Gross Margin19.19%+47.3%
- EBITDA Margin-138.09%-56.0%
- Operating Margin-149.06%-55.5%
- Net Margin-140.8%+5.8%
- ROE-63.86%+33.7%
MDWD Key Insights
MediWound Ltd. (MDWD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 21.0% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 14.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MDWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDWD Price & Volume
MediWound Ltd. (MDWD) stock price & volume — 10-year historical chart
Loading chart...
MDWD Growth Metrics
MediWound Ltd. (MDWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.65%
5 Years-4.87%
3 Years-13.82%
TTM-24.64%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8.28%
Return on Capital
10 Years-34.25%
5 Years-44.21%
3 Years-39.31%
Last Year-47.03%
MDWD Recent Earnings
MediWound Ltd. (MDWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 27, 2026Metric
Actual
Est
EPS
$0.23+64.6%
$0.65
Rev
$1M-56.2%
$3M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.56+13.8%
$0.65
Rev
$2M-55.5%
$4M
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.24+70.4%
$0.81
Rev
$5M+160.1%
$2M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.23-123.6%
$0.55
Rev
$6M-13.0%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 27, 2026 | $0.23vs $0.65+64.6% | $1Mvs $3M-56.2% |
| Q2 2026 | Mar 5, 2026 | $0.56vs $0.65+13.8% | $2Mvs $4M-55.5% |
| Q4 2025 | Nov 20, 2025 | $0.24vs $0.81+70.4% | $5Mvs $2M+160.1% |
| Q3 2025 | Aug 14, 2025 | $1.23vs $0.55-123.6% | $6Mvs $7M-13.0% |
Based on last 12 quarters of dataView full earnings history →
MDWD Peer Comparison
MediWound Ltd. (MDWD) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SLXN | 881.89K | 2.73 | -0.03 | -5.17% | 0.18 | |||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 BLFS | 1.27B | 26.04 | -104.16 | 16.97% | -10.52% | -2.91% | 0.05 | |
 KROS | 340.78M | 10.65 | 4.63 | 67.75% | -256.6% | -17.04% | 0.06 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 XTLB | 279.46K | 2.54 | -0.26 | -227.72% | -25.53% | 0.03 | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare MDWD vs Peers
MediWound Ltd. (MDWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDWD Income Statement
MediWound Ltd. (MDWD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.5M | 3.4M | 31.79M | 21.76M | 23.76M | 26.5M | 18.69M | 20.22M | 16.96M | 14.48M |
Revenue Growth % | 60.21% | 36.26% | 834.7% | -31.54% | 9.19% | 11.5% | -29.48% | 8.22% | -16.14% | -24.64% |
Cost of Goods Sold | 1.58M | 2.09M | 11.85M | 14.22M | 14.99M | 13.33M | 15.11M | 17.59M | 13.71M | 11.64M |
COGS % of Revenue | 63.22% | 61.39% | 37.27% | 65.33% | 63.09% | 50.31% | 80.85% | 86.97% | 80.81% | - |
Gross Profit | 918K▲ 0% | 1.31M▲ 43.0% | 19.94M▲ 1418.7% | 7.54M▼ 62.2% | 8.77M▲ 16.2% | 13.16M▲ 50.1% | 3.58M▼ 72.8% | 2.63M▼ 26.4% | 3.25M▲ 23.5% | 2.84M▲ 0% |
Gross Margin % | 36.78% | 38.61% | 62.73% | 34.67% | 36.91% | 49.69% | 19.15% | 13.03% | 19.19% | 19.61% |
Gross Profit Growth % | 253% | 43.03% | 1418.66% | -62.16% | 16.25% | 50.1% | -72.82% | -26.38% | 23.54% | - |
Operating Expenses | 14.61M | 5.27M | 15.45M | 16.39M | 19.99M | 20.83M | 19.08M | 22.02M | 28.53M | 30.87M |
OpEx % of Revenue | 585.14% | 155.04% | 48.59% | 75.29% | 84.13% | 78.6% | 102.1% | 108.87% | 168.25% | - |
Selling, General & Admin | 9.09M | 7.94M | 9.06M | 8.5M | 9.45M | 10.37M | 11.38M | 12.91M | 13.93M | 14.41M |
SG&A % of Revenue | 364.06% | 233.58% | 28.5% | 39.04% | 39.78% | 39.14% | 60.89% | 63.84% | 82.11% | - |
Research & Development | 5.46M | 4.07M | 4.97M | 7.7M | 10.26M | 10.18M | 7.47M | 8.88M | 14.32M | 16.62M |
R&D % of Revenue | 218.83% | 119.73% | 15.63% | 35.37% | 43.16% | 38.42% | 39.96% | 43.9% | 84.44% | - |
Other Operating Expenses | 56K | -6.74M | 1.42M | 190K | 283K | 274K | 235K | 228K | 288K | -155K |
Operating Income | -13.69M▲ 0% | -3.96M▲ 71.1% | 4.49M▲ 213.5% | -8.84M▼ 296.8% | -11.22M▼ 26.9% | -7.66M▲ 31.7% | -15.5M▼ 102.3% | -19.38M▼ 25.0% | -25.28M▼ 30.4% | -28.03M▲ 0% |
Operating Margin % | -548.36% | -116.44% | 14.13% | -40.62% | -47.22% | -28.91% | -82.96% | -95.85% | -149.06% | -193.62% |
Operating Income Growth % | 32.09% | 71.07% | 213.46% | -296.75% | -26.93% | 31.73% | -102.34% | -25.04% | -30.43% | - |
EBITDA | -13.12M | -3.38M | 5.64M | -7.75M | -9.98M | -6.39M | -14.2M | -17.9M | -23.42M | -26.15M |
EBITDA Margin % | -525.64% | -99.47% | 17.75% | -35.61% | -42.01% | -24.11% | -75.98% | -88.51% | -138.09% | -180.63% |
EBITDA Growth % | 32.94% | 74.21% | 266.78% | -237.36% | -28.81% | 36% | -122.23% | -26.07% | -30.84% | -34.81% |
D&A (Non-Cash Add-back) | 567K | 577K | 1.15M | 1.09M | 1.24M | 1.27M | 1.3M | 1.48M | 1.86M | 1.88M |
EBIT | -13.71M | -4.77M | 2.99M | -8.44M | -12.62M | -19.52M | -6.1M | -29.41M | -23.33M | -26.09M |
Net Interest Income | 349K | 412K | 227K | 97K | -156K | 108K | 2.01M | 1.49M | 1.2M | -2.95M |
Interest Income | 349K | 412K | 434K | 297K | 11K | 270K | 2.34M | 2.05M | 1.86M | 5.04M |
Interest Expense | 0 | 0 | 207K | 200K | 167K | 162K | 335K | 561K | 663K | 7.99M |
Other Income/Expense | -846K | -1.71M | -2.43M | -436K | -2.3M | -11.86M | 8.97M | -10.78M | 1.57M | 2.08M |
Pretax Income | -14.53M▲ 0% | -5.67M▲ 61.0% | 2.07M▲ 136.5% | -9.28M▼ 549.0% | -13.52M▼ 45.8% | -19.52M▼ 44.3% | -6.53M▲ 66.5% | -30.16M▼ 361.8% | -23.71M▲ 21.4% | -25.96M▲ 0% |
Pretax Margin % | -582.25% | -166.57% | 6.5% | -42.62% | -56.91% | -73.68% | -34.95% | -149.16% | -139.81% | -179.28% |
Income Tax | 0 | 0 | 0 | 0 | 27K | 78K | 185K | 61K | 169K | 147K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.2% | -0.4% | -2.83% | -0.2% | -0.71% | -0.57% |
Net Income | -22.15M▲ 0% | -1.06M▲ 95.2% | 4.96M▲ 568.8% | -9.2M▼ 285.6% | -13.55M▼ 47.4% | -19.6M▼ 44.6% | -6.72M▲ 65.7% | -30.22M▼ 350.0% | -23.88M▲ 21.0% | -26.11M▲ 0% |
Net Margin % | -887.38% | -31.08% | 15.59% | -42.26% | -57.03% | -73.97% | -35.94% | -149.46% | -140.8% | -180.3% |
Net Income Growth % | -17.28% | 95.23% | 568.78% | -285.59% | -47.36% | -44.63% | 65.73% | -350.03% | 20.99% | -23.01% |
Net Income (Continuing) | -14.53M | -5.67M | 2.07M | -9.28M | -13.55M | -19.6M | -6.72M | -30.22M | -23.88M | -26.11M |
Discontinued Operations | -7.62M | 4.61M | 2.89M | 80K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -6.64▲ 0% | -0.28▲ 95.8% | 1.26▲ 550.0% | -2.38▼ 288.9% | -3.48▼ 46.2% | -3.93▼ 12.9% | -0.75▲ 80.9% | -3.03▼ 304.0% | -2.10▲ 30.7% | -2.03▲ 0% |
EPS Growth % | -9.75% | 95.78% | 550% | -288.89% | -46.22% | -12.93% | 80.92% | -304% | 30.69% | -8.28% |
EPS (Basic) | -6.64 | -0.28 | 1.26 | -2.38 | -3.48 | -3.93 | -0.75 | -3.03 | -2.10 | - |
Diluted Shares Outstanding | 3.33M | 3.87M | 3.88M | 3.89M | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M | 12.87M |
Basic Shares Outstanding | 3.33M | 3.87M | 3.88M | 3.89M | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M | 12.87M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MDWD Balance Sheet
MediWound Ltd. (MDWD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 41.52M | 32.71M | 35.62M | 26.19M | 14.95M | 45.84M | 49.7M | 52.16M | 59.96M | 52.17M |
Cash & Short-Term Investments | 36.07M | 23.63M | 29.46M | 21.58M | 11.05M | 33.9M | 41.54M | 43.16M | 53.14M | 44.65M |
Cash Only | 36.07M | 6.72M | 7.24M | 17.38M | 11.05M | 33.9M | 11.87M | 9.15M | 4.8M | 44.65M |
Short-Term Investments | 0 | 16.92M | 22.04M | 4.02M | 0 | 0 | 29.68M | 34.01M | 48.34M | 0 |
Accounts Receivable | 3.44M | 7.27M | 4.33M | 2.84M | 2.27M | 9.7M | 4.42M | 5.85M | 2.37M | 2.75M |
Days Sales Outstanding | 502.46 | 780.01 | 49.77 | 47.63 | 34.82 | 133.56 | 86.32 | 105.63 | 51.05 | 113.18 |
Inventory | 1.89M | 1.68M | 1.61M | 1.38M | 1.2M | 1.96M | 2.85M | 2.69M | 4.09M | 4.77M |
Days Inventory Outstanding | 436.24 | 293.68 | 49.69 | 35.43 | 29.22 | 53.75 | 68.76 | 55.87 | 109.01 | 134.15 |
Other Current Assets | 0 | 0 | 408K | 257K | 0 | 363K | 167K | 0 | 0 | 0 |
Total Non-Current Assets | 2.62M | 2.56M | 4.97M | 4.88M | 4.79M | 4.18M | 16.76M | 21.33M | 26.29M | 27.82M |
Property, Plant & Equipment | 1.92M | 2.02M | 4.53M | 4.51M | 4.03M | 3.58M | 15.93M | 20.8M | 25.79M | 27.33M |
Fixed Asset Turnover | 1.30x | 1.68x | 7.01x | 4.82x | 5.90x | 7.40x | 1.17x | 0.97x | 0.66x | 0.57x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 635K | 495K | 429K | 363K | 297K | 231K | 165K | 99K | 33K | 17K |
Long-Term Investments | 0 | 0 | 0 | 0 | 469K | 364K | 490K | 439K | 467K | 1.89M |
Other Non-Current Assets | 56K | 48K | 6K | -4.88M | -4.32M | -3.81M | 183K | 0 | 0 | 0 |
Total Assets | 44.13M▲ 0% | 35.28M▼ 20.1% | 40.59M▲ 15.1% | 31.07M▼ 23.5% | 19.74M▼ 36.5% | 50.02M▲ 153.3% | 66.46M▲ 32.9% | 73.5M▲ 10.6% | 86.25M▲ 17.4% | 79.98M▲ 0% |
Asset Turnover | 0.06x | 0.10x | 0.78x | 0.70x | 1.20x | 0.53x | 0.28x | 0.28x | 0.20x | 0.18x |
Asset Growth % | 23.41% | -20.07% | 15.06% | -23.45% | -36.45% | 153.32% | 32.88% | 10.59% | 17.36% | 76.53% |
Total Current Liabilities | 5.43M | 4.9M | 10.37M | 8.27M | 10.72M | 12.06M | 10.83M | 26.54M | 25.71M | 21.65M |
Accounts Payable | 3.25M | 2.71M | 4.07M | 2.99M | 4.69M | 5.66M | 4.22M | 4.1M | 3.61M | 7.41M |
Days Payables Outstanding | 751.97 | 474.6 | 125.28 | 76.81 | 114.26 | 154.86 | 102.03 | 85 | 96.06 | 199.16 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K | 623K | 929K |
Deferred Revenue (Current) | 131K | 198K | 249K | 462K | 543K | 63K | 24K | 12K | 0 | 0 |
Other Current Liabilities | 0 | 452K | 3.74M | 2.9M | 3.85M | 3.87M | 1.86M | 17.73M | 18.43M | 7.72M |
Current Ratio | 7.64x | 6.68x | 3.43x | 3.17x | 1.39x | 3.80x | 4.59x | 1.97x | 2.33x | 2.41x |
Quick Ratio | 7.30x | 6.34x | 3.28x | 3.00x | 1.28x | 3.64x | 4.33x | 1.86x | 2.17x | 2.19x |
Cash Conversion Cycle | 186.73 | 599.09 | -25.82 | 6.25 | -50.22 | 32.44 | 53.05 | 76.49 | 63.99 | 48.17 |
Total Non-Current Liabilities | 29.08M | 21.41M | 15.05M | 15.53M | 13.61M | 27.05M | 16.74M | 15.8M | 8.62M | 16.91M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.01M | 1.74M | 1.39M | 846K | 6.35M | 6.51M | 8.15M | 32.62M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 28.09M | 20.25M | 11.91M | 12.56M | 12.1M | 26.2M | 10.39M | 8.55M | 472K | 8.79M |
Total Liabilities | 34.52M | 26.3M | 25.42M | 23.8M | 24.33M | 39.1M | 34.86M | 42.34M | 34.33M | 38.56M |
Total Debt | 0 | 0 | 2.01M | 1.74M | 1.39M | 846K | 6.35M | 6.93M | 8.77M | 8.13M |
Net Debt | -36.07M | -6.72M | -5.24M | -15.63M | -9.65M | -33.05M | -5.52M | -2.22M | 3.98M | -36.52M |
Debt / Equity | - | - | 0.13x | 0.24x | - | 0.08x | 0.20x | 0.22x | 0.20x | 0.20x |
Debt / EBITDA | - | - | 0.36x | - | - | - | - | - | - | -0.31x |
Net Debt / EBITDA | - | - | -0.93x | - | - | - | - | - | - | 1.40x |
Interest Coverage | - | - | 14.45x | -42.22x | -75.57x | -120.50x | -18.22x | -52.43x | -35.19x | -3.26x |
Total Equity | 9.62M▲ 0% | 8.97M▼ 6.7% | 15.17M▲ 69.1% | 7.27M▼ 52.1% | -4.58M▼ 163.0% | 10.91M▲ 338.2% | 31.59M▲ 189.5% | 31.15M▼ 1.4% | 43.63M▲ 40.1% | 41.42M▲ 0% |
Equity Growth % | 23.81% | -6.74% | 69.07% | -52.06% | -163.01% | 338.19% | 189.49% | -1.4% | 40.06% | 131.61% |
Book Value per Share | 2.89 | 2.32 | 3.91 | 1.87 | -1.18 | 2.19 | 3.51 | 3.13 | 3.84 | 3.22 |
Total Shareholders' Equity | 9.62M | 8.97M | 15.17M | 7.27M | -4.58M | 10.91M | 31.59M | 31.15M | 43.63M | 41.42M |
Common Stock | 75K | 75K | 75K | 75K | 75K | 143K | 184K | 215K | 258K | 0 |
Retained Earnings | -129.41M | -130.72M | -125.76M | -134.96M | -148.51M | -168.11M | -174.82M | -205.05M | -228.93M | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -38K | -25K | -17K | -40K | -19K | -5K | -18K | -11K | -32K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDWD Cash Flow Statement
MediWound Ltd. (MDWD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.45M | -12.15M | 8.29M | -6.89M | -8.92M | -11.88M | -10.46M | -13.62M | -14.53M | -17.86M |
Operating CF Margin % | -659.25% | -357.37% | 26.08% | -31.68% | -37.52% | -44.86% | -56% | -67.37% | -85.68% | - |
Operating CF Growth % | -0.06% | 26.14% | 168.2% | -183.18% | -29.31% | -33.3% | 11.95% | -30.19% | -6.65% | -160.3% |
Net Income | -22.15M | -1.06M | 4.96M | -9.2M | -13.55M | -19.6M | -6.72M | -30.22M | -23.88M | -26.11M |
Depreciation & Amortization | 567K | 577K | 1.15M | 1.09M | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M | 1.88M |
Stock-Based Compensation | 1.36M | 645K | 1.23M | 1.32M | 1.67M | 1.95M | 1.94M | 3.14M | 0 | 1.51M |
Deferred Taxes | -1.64M | 201K | -1.86M | -373K | -124K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 7.85M | -11.51M | -1.69M | 323K | 1.69M | 11.74M | -9.33M | 10.71M | 2.87M | -915.33K |
Working Capital Changes | -2.45M | -1.01M | 4.49M | -61K | 162K | -7.24M | 2.34M | 1.27M | 4.77M | 5.78M |
Change in Receivables | 28K | -211K | -3.55M | 1.39M | 929K | -7.58M | 4.76M | -1.02M | 4.88M | 3.64M |
Change in Inventory | -1.04M | 206K | 67K | 141K | 257K | -721K | -906K | 187K | -1.36M | -1.16M |
Change in Payables | -135K | -536K | 1.35M | -1.1M | 1.72M | 414K | -594K | 406K | 2.35M | 2.31M |
Cash from Investing | 437K | -17.04M | -6.9M | 17.39M | 3.55M | -481K | -34.32M | -8.4M | -19.54M | 1.49M |
Capital Expenditures | -1.07M | -534K | -792K | -923K | -489K | -555K | -6.46M | -6.27M | -5.5M | -6.46M |
CapEx % of Revenue | 43.07% | 15.7% | 2.49% | 4.24% | 2.06% | 2.09% | 34.59% | 31.02% | 32.46% | 44.62% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 349K | -16.51M | -1.05M | 274K | 35K | 74K | -27.86M | -2.12M | 0 | 19.78M |
Cash from Financing | 23M | 46K | -1.01M | -629K | -1.05M | 35.76M | 22.92M | 19.39M | 29.62M | 30.48M |
Debt Issued (Net) | 0 | 0 | -630K | -508K | 0 | 0 | 0 | -928K | 0 | -289K |
Equity Issued (Net) | 22.66M | 0 | 0 | 0 | 0 | 38.38M | 24.91M | 22.16M | 31.05M | 32.02M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 337K | 46K | -376K | -121K | -1.05M | -2.62M | -1.99M | -1.84M | -1.43M | -1.25M |
Net Change in Cash | 7.2M▲ 0% | -29.35M▼ 507.5% | 526K▲ 101.8% | 10.13M▲ 1826.6% | -6.33M▼ 162.5% | 22.85M▲ 461.0% | -22.03M▼ 196.4% | -2.71M▲ 87.7% | -4.36M▼ 60.7% | 13.99M▲ 0% |
Free Cash Flow | -17.53M▲ 0% | -12.69M▲ 27.6% | 7.5M▲ 159.1% | -7.82M▼ 204.3% | -9.4M▼ 20.3% | -12.44M▼ 32.3% | -16.93M▼ 36.1% | -19.9M▼ 17.5% | -20.04M▼ 0.7% | -24.32M▲ 0% |
FCF Margin % | -702.32% | -373.07% | 23.58% | -35.92% | -39.58% | -46.95% | -90.6% | -98.39% | -118.14% | -167.94% |
FCF Growth % | -2.24% | 27.62% | 159.09% | -204.28% | -20.3% | -32.27% | -36.09% | -17.53% | -0.69% | -27.32% |
FCF per Share | -5.26 | -3.28 | 1.93 | -2.01 | -2.42 | -2.49 | -1.88 | -2.00 | -1.76 | -1.89 |
FCF Conversion (FCF/Net Income) | 0.74x | 11.50x | 1.67x | 0.75x | 0.66x | 0.61x | 1.56x | 0.45x | 0.61x | 0.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDWD Key Ratios
MediWound Ltd. (MDWD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -254.73% | -11.37% | 41.05% | -81.96% | -1007.51% | -619.05% | -31.6% | -96.33% | -63.86% | -67.22% |
Return on Invested Capital (ROIC) | - | - | 55.29% | -844.59% | - | - | -589.54% | -52.85% | -49.54% | -95.24% |
Gross Margin | 36.78% | 38.61% | 62.73% | 34.67% | 36.91% | 49.69% | 19.15% | 13.03% | 19.19% | 19.61% |
Net Margin | -887.38% | -31.08% | 15.59% | -42.26% | -57.03% | -73.97% | -35.94% | -149.46% | -140.8% | -180.3% |
Debt / Equity | - | - | 0.13x | 0.24x | - | 0.08x | 0.20x | 0.22x | 0.20x | 0.20x |
Interest Coverage | - | - | 14.45x | -42.22x | -75.57x | -120.50x | -18.22x | -52.43x | -35.19x | -3.26x |
FCF Conversion | 0.74x | 11.50x | 1.67x | 0.75x | 0.66x | 0.61x | 1.56x | 0.45x | 0.61x | 0.93x |
Revenue Growth | 60.21% | 36.26% | 834.7% | -31.54% | 9.19% | 11.5% | -29.48% | 8.22% | -16.14% | -24.64% |
Related:MDWD Dividend History·MDWD Revenue History·MDWD Price History·MDWD P/E History·MDWD Financial Ratios·MDWD Institutional Holders
MDWD Frequently Asked Questions
MediWound Ltd. (MDWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MediWound Ltd. (MDWD) reported $14.5M in revenue for fiscal year 2025.
MediWound Ltd. (MDWD) saw revenue decline by 16.1% over the past year.
MediWound Ltd. (MDWD) reported a net loss of $26.1M for fiscal year 2025.
Dividend & Returns
MediWound Ltd. (MDWD) has a return on equity (ROE) of -63.9%. Negative ROE indicates the company is unprofitable.
MediWound Ltd. (MDWD) had negative free cash flow of $24.3M in fiscal year 2025, likely due to heavy capital investments.